{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:52:07Z","timestamp":1780519927085,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82474009"],"award-info":[{"award-number":["No.82474009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Hunan Provincial Natural Science Foundation of China","award":["No. 2023JJ60513"],"award-info":[{"award-number":["No. 2023JJ60513"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01951-1","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:55:15Z","timestamp":1764687315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"chictr2500103582","registry":"10.18810\/chictr"}],"author":[{"given":"Hui","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianda","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jie\u00a0Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"suppl_1","key":"1951_CR1","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","volume":"215","author":"LK Logan","year":"2017","unstructured":"Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28\u201336.","journal-title":"J Infect Dis"},{"key":"1951_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.127249","volume":"266","author":"J Ma","year":"2023","unstructured":"Ma J, Song X, Li M, et al. Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res. 2023;266:127249.","journal-title":"Microbiol Res"},{"issue":"3","key":"1951_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"key":"1951_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0119-2022","author":"M Bassetti","year":"2022","unstructured":"Bassetti M, Magn\u00e8 F, Giacobbe DR, et al. New antibiotics for gram-negative pneumonia. Eur Respir Rev. 2022. https:\/\/doi.org\/10.1183\/16000617.0119-2022.","journal-title":"Eur Respir Rev"},{"issue":"12","key":"1951_CR5","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40265-024-02102-8","volume":"84","author":"C Hidalgo-Tenorio","year":"2024","unstructured":"Hidalgo-Tenorio C, Bou G, Oliver A, et al. The challenge of treating infections caused by Metallo-\u03b2-lactamase-producing Gram-negative bacteria: a narrative review. Drugs. 2024;84(12):1519\u201339.","journal-title":"Drugs"},{"issue":"10325","key":"1951_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJ Murray","year":"2022","unstructured":"Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"4","key":"1951_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/21505594.2017.1292196","volume":"8","author":"EM Trecarichi","year":"2017","unstructured":"Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence. 2017;8(4):470\u201384.","journal-title":"Virulence"},{"key":"1951_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-19","author":"MD Barnes","year":"2019","unstructured":"Barnes MD, Taracila MA, Good CE, et al. Nacubactam enhances meropenem activity against carbapenem-resistant Klebsiella pneumoniae producing KPC. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00432-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1951_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10096-025-05080-1","volume":"44","author":"M Boattini","year":"2025","unstructured":"Boattini M, Gaibani P, Comini S, et al. In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-\u03b2-lactamase producers. Eur J Clin Microbiol Infect Dis. 2025;44(5):1041\u201368.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"1951_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00924-24","volume":"68","author":"T Blanco-Mart\u00edn","year":"2024","unstructured":"Blanco-Mart\u00edn T, L\u00f3pez-Hern\u00e1ndez I, Aracil B, et al. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of \u03b2-lactams and the novel \u03b2-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother. 2024;68(11):e0092424.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1951_CR11","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/jac\/dkv166","volume":"70","author":"A Morinaka","year":"2015","unstructured":"Morinaka A, Tsutsumi Y, Yamada M, et al. OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u201cenhancer.\u201d J Antimicrob Chemother. 2015;70(10):2779\u201386.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"1951_CR12","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1093\/jac\/dkv239","volume":"70","author":"DM Livermore","year":"2015","unstructured":"Livermore DM, Mushtaq S, Warner M, et al. Activity of OP0595\/\u03b2-lactam combinations against gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing \u03b2-lactamases. J Antimicrob Chemother. 2015;70(11):3032\u201341.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1951_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1128\/AAC.02184-15","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore DM, Warner M, Mushtaq S, et al. Interactions of OP0595, a novel triple-action diazabicyclooctane, with \u03b2-lactams against OP0595-resistant enterobacteriaceae mutants. Antimicrob Agents Chemother. 2016;60(1):554\u201360.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1951_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jac\/dkae443","volume":"80","author":"Y Igarashi","year":"2025","unstructured":"Igarashi Y, Taguchi K, Enoki Y, et al. Simulated achievement rate of \u03b2-lactams\/nacubactam treatment in humans using instantaneous MIC-based PK\/PD analysis. J Antimicrob Chemother. 2025;80(2):547\u201353.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1951_CR15","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s11095-023-03608-8","volume":"40","author":"Y Igarashi","year":"2023","unstructured":"Igarashi Y, Takemura W, Liu X, et al. In vivo pharmacokinetic\/pharmacodynamic analysis of the efficacy of the cefepime\/nacubactam combination against \u03b2-lactamase-producing enterobacterales based on the instantaneous MIC concept. Pharm Res. 2023;40(10):2423\u201331.","journal-title":"Pharm Res"},{"issue":"5","key":"1951_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106330","volume":"57","author":"M Hagihara","year":"2021","unstructured":"Hagihara M, Kato H, Sugano T, et al. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel \u03b2-lactamase inhibitor, nacubactam, against carbapenem-resistant and\/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model. Int J Antimicrob Agents. 2021;57(5):106330.","journal-title":"Int J Antimicrob Agents"},{"key":"1951_CR17","doi-asserted-by":"crossref","unstructured":"Asano M, Sato H, Morita J, et al. 1287. Pharmacokinetics, safety, and tolerability of nacubactam after single coadministration with \u03b2-lactams in Japanese healthy subjects [J]. 2020, 7(Supplement_1): S659-S","DOI":"10.1093\/ofid\/ofaa439.1470"},{"key":"1951_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02229-19","author":"NL Mallalieu","year":"2020","unstructured":"Mallalieu NL, Winter E, Fettner S, et al. Safety and pharmacokinetic characterization of nacubactam, a novel \u03b2-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.02229-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1951_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cpdd.369","volume":"7","author":"DJ Liu","year":"2017","unstructured":"Liu DJ, Collaku A. Bioequivalence and safety of twice-daily sustained-release paracetamol (acetaminophen) compared with 3- and 4-times-daily paracetamol: a repeat-dose, crossover pharmacokinetic study in healthy volunteers. Clin Pharmacol Drug Dev. 2017;7(1):77\u201386.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01951-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:29:45Z","timestamp":1767677385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01951-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1951"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01951-1","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lei Diao and Nianda Yu are the employees of Shanghai Fosun Pharmaceutical Development Co., Ltd. Hong Chen and Xi Peng are the employees of Fobeni Healthcom Pharmaceutical Jiangsu Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was registered with the Chinese Clinical Trial Registry (Registration No. ChiCTR2500103582) and approved by the Ethics Committee of the Third Xiangya Hospital, Central South University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"96"}}